Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Demyelination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Demyelination. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2022-002718-17 Sponsor Protocol Number: IMVT-1401-2401 Start Date*: 2023-06-19
    Sponsor Name:Immunovant Sciences, GmbH
    Full Title: A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077384 Chronic inflammatory demyelinating polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000698-38 Sponsor Protocol Number: MD1003CT2014-01AMN Start Date*: 2014-08-13
    Sponsor Name:MEDDAY SAS
    Full Title: MD1003 IN ADRENOMYELONEUROPATHY: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY
    Medical condition: Adrenomyeloneuropathy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10069075 Adrenomyeloneuropathy without cerebral involvement LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-001161-14 Sponsor Protocol Number: CAMMS 323 Start Date*: 2007-08-24
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) SE (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-001162-32 Sponsor Protocol Number: CAMMS 32400507 Start Date*: 2007-12-24
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patie...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) SE (Completed) DE (Completed) FR (Completed) BE (Completed) ES (Completed) CZ (Completed) AT (Completed) IT (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016140-39 Sponsor Protocol Number: IDI-GAD-2009-01 Start Date*: 2010-01-19
    Sponsor Name:Institut Diagnostic per la Imatge
    Full Title: MRI in Clinically Isolated Syndromes and relapsing multiple sclerosis after single dose (0.1 mmol/kg) and cumulative dose (0.1 + 0.1 mmol/kg) of GADOVIST at 3.0T Estudio de resonancia magnética 3...
    Medical condition: Realce de contraste en resonancia magnética en pacientes con Síndrome Clínico Aislado o recaída de Esclerosis Múltiple con resonancia magnética anormal anterior después de la administración de dosi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004988-32 Sponsor Protocol Number: NL46993.078.13 Start Date*: 2014-01-22
    Sponsor Name:Erasmus MC
    Full Title: Rotterdam Observational Study in CIDP of Pharmacokinetics of Intravenous γ-globulin
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016703-35 Sponsor Protocol Number: NAPMSv3.2 Start Date*: 2010-01-08
    Sponsor Name:Dansk Multipel Sclerose Center
    Full Title: Natalizumabbehandling af progressiv multipel sklerose
    Medical condition: Secondary progressive multiple sclerosis and primary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063400 Secondary progressive multiple sclerosis LLT
    12.0 10063401 Primary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-017349-77 Sponsor Protocol Number: TIGET-MLD Start Date*: 2010-03-15
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: A Phase I/II clinical trial of hematopoietic stem cell gene therapy for the treatment of Metachromatic Leukodystrophy
    Medical condition: metachromatic leukodystrophy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024381 PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005150-34 Sponsor Protocol Number: DRIP1.04 Start Date*: 2014-11-18
    Sponsor Name:Erasmus MC
    Full Title: Dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10035325 Plasma immunoglobulin G decreased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000635-13 Sponsor Protocol Number: EMMA Start Date*: 2018-06-08
    Sponsor Name:Universität Leipzig
    Full Title: Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption
    Medical condition: Multiple Sclerosis (MS), acute episode
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002782-32 Sponsor Protocol Number: C13006 Start Date*: 2009-03-02
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative C...
    Medical condition: Moderate to Severe Ulcerative Colitis Colitis ulcerosa moderada o grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) HU (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) DK (Completed) IS (Completed) PT (Prematurely Ended) BE (Completed) FR (Completed) GB (Completed) BG (Completed) IT (Completed) MT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003056-36 Sponsor Protocol Number: CBAF312A2304 Start Date*: 2012-10-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro...
    Medical condition: Secondary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IE (Completed) DE (Prematurely Ended) CZ (Completed) SK (Completed) NL (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) SE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) LV (Completed) GR (Completed) LT (Completed) EE (Completed) BE (Prematurely Ended) PL (Completed) BG (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002537-41 Sponsor Protocol Number: 20170104 Start Date*: 2022-01-06
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Sev...
    Medical condition: Moderate to Severe Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) RO (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020338-25 Sponsor Protocol Number: WA25046 Start Date*: 2010-11-02
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis
    Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) ES (Ongoing) BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) AT (Completed) FI (Completed) IT (Completed) GR (Completed) BG (Completed) DK (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001150-10 Sponsor Protocol Number: ECU-NMO-301 Start Date*: 2013-12-12
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)
    Medical condition: Neuromyelitis Optica
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Completed) GB (Prematurely Ended) ES (Completed) AT (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) FR (Completed) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002783-33 Sponsor Protocol Number: C13007 Start Date*: 2009-03-02
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn?s Dise...
    Medical condition: Moderate to Severe Crohn's Disease Enfermedad de Crohn moderada o grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) HU (Completed) SK (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) IS (Completed) PT (Prematurely Ended) DK (Completed) FR (Completed) BE (Completed) MT (Completed) GB (Completed) BG (Completed) SE (Completed) IT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001152-12 Sponsor Protocol Number: EFC6260 Start Date*: 2007-10-15
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 1...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FI (Completed) FR (Completed) AT (Completed) HU (Completed) DK (Completed) EE (Completed) SK (Completed) BG (Completed) LT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004935-18 Sponsor Protocol Number: GNC-004 Start Date*: 2017-04-12
    Sponsor Name:GeNeuro SA
    Full Title: A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001145-40 Sponsor Protocol Number: 20021618 Start Date*: 2012-03-07
    Sponsor Name:Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
    Full Title: Open-label Extension Treatment with TNFR:Fc for Participating Patients in TNFR:Fc Clinical Trials
    Medical condition: Rheumatoid arthritis (RA) in adults and juvenile idiopathic arthritis (JIA) for subjects who did not respond to conventional DMARDS
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000176-15 Sponsor Protocol Number: IZN-101 Start Date*: 2018-06-19
    Sponsor Name:Izana Bioscience Limited
    Full Title: A phase 2a proof of concept, randomised, double-blind, placebo-controlled study to evaluate the safety/tolerability and efficacy of 4 subcutaneous injections of namilumab (150 mg) given over 10 wee...
    Medical condition: moderate-to-severe axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:24:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA